Antares Pharma Return on Equity

Antares Pharma (ATRS) currently reports a ROE of 22.86%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore Antares Pharma's ROE history and peer comparisons.

Antares Pharma's ROE of 22.86% is higher than the Healthcare sector average of 13.26%. That is roughly 72.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Antares Pharma's current 22.86% should be judged against Healthcare norms (sector average: 13.26%) and against ATRS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 22.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Antares Pharma, and consider following ATRS for alerts when major investors trade the stock.

Antares Pharma is classified in the Healthcare sector. On ROE, it currently shows 22.86% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATRS with unrelated industries.